Latest News

United Kingdom first to grant licence for Teva’s ophthalmology biosimilar Ongavia (ranibizumab)▼

United Kingdom first to grant licence for Teva’s ophthalmology biosimilar Ongavia (ranibizumab)▼

Teva to Present Latest Research From Neurology Portfolio at the 2022 American Psychiatric Associatio...

Teva to Present Latest Research From Neurology Portfolio at the 2022 American Psychiatric Association Ann

Teva Announces New Findings Highlighting Potential of ProAir® Digihaler® (albuterol sulfate) Inhalat...

Teva Announces New Findings Highlighting Potential of ProAir® Digihaler® (albuterol sulfate) Inhalation P

Teva to Present Findings on Short-Acting Beta Agonist (SABA) Use in Asthma Patients and the Potentia...

Teva to Present Findings on Short-Acting Beta Agonist (SABA) Use in Asthma Patients and the Potential of

Teva Publishes 2021 ESG Progress Report, Showcasing Further Integration of ESG Into Business, Robust...

Teva Publishes 2021 ESG Progress Report, Showcasing Further Integration of ESG Into Business, Robust Targ

Teva Reports First Quarter 2022 Financial Results

Teva Reports First Quarter 2022 Financial Results

Teva Announces Settlement with Lupin Resolving AUSTEDO® (deutetrabenazine) Patent Dispute

Teva Announces Settlement with Lupin Resolving AUSTEDO® (deutetrabenazine) Patent Dispute

Teva and MedinCell Receive Complete Response Letter for TV-46000/mdc-IRM

Teva and MedinCell Receive Complete Response Letter for TV-46000/mdc-IRM

Teva to Host Conference Call to Discuss First Quarter 2022 Financial Results at 8 a.m. ET on May 3, ...

Teva to Host Conference Call to Discuss First Quarter 2022 Financial Results at 8 a.m. ET on May 3, 2022

Teva to Present New Analyses of AJOVY® (fremanezumab-vfrm) Injection and AUSTEDO® (deutetrabenazine)...

Teva to Present New Analyses of AJOVY® (fremanezumab-vfrm) Injection and AUSTEDO® (deutetrabenazine) Tabl

Teva Reaches Agreement With Florida to Settle the State’s Opioid-Related Claims

Teva Reaches Agreement With Florida to Settle the State’s Opioid-Related Claims

Teva Issues Voluntary Nationwide Recall of One Lot of IDArubicin Hydrochloride Injection USP 5 mg/5 ...

Teva Issues Voluntary Nationwide Recall of One Lot of IDArubicin Hydrochloride Injection USP 5 mg/5 mL Due to the Presence of Particulate Matter

Teva Reaches Agreement With Rhode Island to Settle Opioid-Related Claims

Teva Reaches Agreement With Rhode Island to Settle Opioid-Related Claims

Teva Announces Donations of Essential Medicines in Support of Ukrainian Refugees

Teva Announces Donations of Essential Medicines in Support of Ukrainian Refugees

Teva Announces Launch of a First Generic Version of Revlimid® (lenalidomide capsules), in the U.S.

Teva Announces Launch of a First Generic Version of Revlimid® (lenalidomide capsules), in the U.S.